Get App
Last Updated : May 20, 2019 05:36 PM IST | Source:

3 Point Analysis | UPL Q4FY19 Review

Sakshi Batra does a 3 Point Analysis of the earnings fine print and shares an outlook on the company.

Moneycontrol News @moneycontrolcom

Post the big ticket acquisition of Arysta LifeScience last year, UPL has reported a subdued set of Q4 results.

While the operating performance (excluding Arysta remained healthy), the combined numbers remained impacted.

Sakshi Batra does a 3 Point Analysis of the earnings fine print and shares an outlook on the company.

Subscribe to Moneycontrol Pro and gain access to curated markets data, exclusive trading recommendations, independent equity analysis, actionable investment ideas, nuanced takes on macro, corporate and policy actions, practical insights from market gurus and much more.
First Published on May 20, 2019 05:29 pm
Follow us on
Available On
PCI DSS Compliant